메뉴 건너뛰기




Volumn 27, Issue 5, 2014, Pages 558-565

Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis

Author keywords

IgG4; Muscle specific tyrosine kinase; Myasthenia gravis; Neuromuscular junction; Pyridostigmine

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MUSCLE SPECIFIC TYROSINE KINASE; NEOSTIGMINE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; RITUXIMAB; UNCLASSIFIED DRUG; AUTOANTIBODY;

EID: 84925787100     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000136     Document Type: Review
Times cited : (30)

References (57)
  • 1
    • 0035105784 scopus 로고    scopus 로고
    • Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
    • Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
    • (2001) Nat Med , vol.7 , pp. 365-368
    • Hoch, W.1    McConville, J.2    Helms, S.3
  • 2
    • 0242336467 scopus 로고    scopus 로고
    • Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis
    • Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(Pt 10):2304-2311.
    • (2003) Brain , vol.126 , pp. 2304-2311
    • Evoli, A.1    Tonali, P.A.2    Padua, L.3
  • 3
    • 0022648551 scopus 로고
    • Myasthenia gravis without acetylcholine-receptor antibody: A distinct disease entity
    • Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1986;1:116-119.
    • (1986) Lancet , vol.1 , pp. 116-119
    • Mossman, S.1    Vincent, A.2    Newsom-Davis, J.3
  • 4
    • 79959324658 scopus 로고    scopus 로고
    • Anti-MuSK antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts
    • Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011;44:36-40.
    • (2011) Muscle Nerve , vol.44 , pp. 36-40
    • Guptill, J.T.1    Sanders, D.B.2    Evoli, A.3
  • 5
    • 77649169688 scopus 로고    scopus 로고
    • Clinical findings in MuSK-antibody positive myasthenia gravis: A U. S.experience
    • Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U. S.experience. Muscle Nerve 2010;41:370-374.
    • (2010) Muscle Nerve , vol.41 , pp. 370-374
    • Pasnoor, M.1    Wolfe, G.I.2    Nations, S.3
  • 6
    • 34548134917 scopus 로고    scopus 로고
    • Clinical and experimental features of MuSK antibody positive MG in Japan
    • Ohta K, Shigemoto K, Fujinami A, et al. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 2007;14:1029-1034.
    • (2007) Eur J Neurol , vol.14 , pp. 1029-1034
    • Ohta, K.1    Shigemoto, K.2    Fujinami, A.3
  • 7
    • 84884989647 scopus 로고    scopus 로고
    • Muscle specific kinase autoimmune myasthenia gravis inchildren: Acase series
    • Skjei KL, Lennon VA, Kuntz NL. Muscle specific kinase autoimmune myasthenia gravis inchildren: acase series. Neuromuscul Disord 2013;23:874-882.
    • (2013) Neuromuscul Disord , vol.23 , pp. 874-882
    • Skjei, K.L.1    Lennon, V.A.2    Kuntz, N.L.3
  • 8
    • 33745061989 scopus 로고    scopus 로고
    • MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis
    • Farrugia ME, Robson MD, Clover L, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006;129(Pt 6):1481-1492.
    • (2006) Brain , vol.129 , pp. 1481-1492
    • Farrugia, M.E.1    Robson, M.D.2    Clover, L.3
  • 9
    • 1642348179 scopus 로고    scopus 로고
    • Detection and characterization of MuSK antibodies in seronegative myasthenia gravis
    • McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-584.
    • (2004) Ann Neurol , vol.55 , pp. 580-584
    • McConville, J.1    Farrugia, M.E.2    Beeson, D.3
  • 10
    • 4444362201 scopus 로고    scopus 로고
    • Muscle-specific receptor tyrosine kinase autoantibodies: A new immunoprecipitation assay
    • Matthews I, Chen S, Hewer R, et al. Muscle-specific receptor tyrosine kinase autoantibodies: a new immunoprecipitation assay. Clin Chim Acta 2004;348:95-99.
    • (2004) Clin Chim Acta , vol.348 , pp. 95-99
    • Matthews, I.1    Chen, S.2    Hewer, R.3
  • 11
    • 46749148845 scopus 로고    scopus 로고
    • Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction
    • Cole RN, Reddel SW, Gervasio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008;63:782-789.
    • (2008) Ann Neurol , vol.63 , pp. 782-789
    • Cole, R.N.1    Reddel, S.W.2    Gervasio, O.L.3    Phillips, W.D.4
  • 12
    • 79952513213 scopus 로고    scopus 로고
    • Autoantibodies to lowdensity lipoprotein receptor-related protein 4 in myasthenia gravis
    • Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to lowdensity lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011;69:418-422.
    • (2011) Ann Neurol , vol.69 , pp. 418-422
    • Higuchi, O.1    Hamuro, J.2    Motomura, M.3    Yamanashi, Y.4
  • 13
    • 84904307500 scopus 로고    scopus 로고
    • A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis
    • Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 2013;52:139-145. A large serological survey of seronegative patients showing a high proportion of patients with Lrp4 antibodies in some sites. However, this prevalence remains to be confirmed by other laboratories, which have previously reported very few cases of patients with Lrp4 antibodies.
    • (2013) J Autoimmun , vol.52 , pp. 139-145
    • Zisimopoulou, P.1    Evangelakou, P.2    Tzartos, J.3
  • 14
    • 84871588214 scopus 로고    scopus 로고
    • The search for new antigenic targets in myasthenia gravis
    • Cossins J, Belaya K, Zoltowska K, et al. The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 2012;1275:123-128.
    • (2012) Ann N Y Acad Sci , vol.1275 , pp. 123-128
    • Cossins, J.1    Belaya, K.2    Zoltowska, K.3
  • 15
    • 46849112624 scopus 로고    scopus 로고
    • IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis
    • Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008;131(Pt 7):1940-1952.
    • (2008) Brain , vol.131 , pp. 1940-1952
    • Leite, M.I.1    Jacob, S.2    Viegas, S.3
  • 16
    • 84897981976 scopus 로고    scopus 로고
    • Autoantibodies to agrin in myasthenia gravis patients
    • Zhang B, Shen C, Bealmear B, et al. Autoantibodies to agrin in myasthenia gravis patients. PLoS One 2014;9:e91816.
    • (2014) PLoS One , vol.9 , pp. e91816
    • Zhang, B.1    Shen, C.2    Bealmear, B.3
  • 17
    • 51649084726 scopus 로고    scopus 로고
    • MuSK-antibody positive myasthenia gravis: Questions from the clinic
    • Sanders DB, Juel VC. MuSK-antibody positive myasthenia gravis: questions from the clinic. J Neuroimmunol 2008;201-202:85-89.
    • (2008) J Neuroimmunol , vol.201-202 , pp. 85-89
    • Sanders, D.B.1    Juel, V.C.2
  • 18
    • 84886746314 scopus 로고    scopus 로고
    • Muscle-specific kinase antibodies: A novel cause of peripheral nerve hyperexcitability?
    • Simon NG, Reddel SW, Kiernan MC, Layzer R. Muscle-specific kinase antibodies: a novel cause of peripheral nerve hyperexcitability? Muscle Nerve 2013;48:819-823.
    • (2013) Muscle Nerve , vol.48 , pp. 819-823
    • Simon, N.G.1    Reddel, S.W.2    Kiernan, M.C.3    Layzer, R.4
  • 19
    • 79751539071 scopus 로고    scopus 로고
    • Muscle specific kinase: Organiser of synaptic membrane domains
    • Ghazanfari N, Fernandez KJ, Murata Y, et al. Muscle specific kinase: organiser of synaptic membrane domains. Int J Biochem Cell Biol 2011;43:295-298.
    • (2011) Int J Biochem Cell Biol , vol.43 , pp. 295-298
    • Ghazanfari, N.1    Fernandez, K.J.2    Murata, Y.3
  • 20
    • 23344453327 scopus 로고    scopus 로고
    • Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter
    • Misgeld T, Kummer TT, Lichtman JW, Sanes JR. Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter. Proc Natl Acad Sci U S A 2005;102:11088-11093.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 11088-11093
    • Misgeld, T.1    Kummer, T.T.2    Lichtman, J.W.3    Sanes, J.R.4
  • 21
    • 20444362083 scopus 로고    scopus 로고
    • Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependent mechanism
    • Lin W, Dominguez B, Yang J, et al. Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a Cdk5-dependent mechanism. Neuron 2005;46:569-579.
    • (2005) Neuron , vol.46 , pp. 569-579
    • Lin, W.1    Dominguez, B.2    Yang, J.3
  • 22
    • 34447277859 scopus 로고    scopus 로고
    • Rapsyn interaction with calpain stabilizes AChR clusters at the neuromuscular junction
    • Chen F, Qian L, Yang ZH, et al. Rapsyn interaction with calpain stabilizes AChR clusters at the neuromuscular junction. Neuron 2007;55:247-260.
    • (2007) Neuron , vol.55 , pp. 247-260
    • Chen, F.1    Qian, L.2    Yang, Z.H.3
  • 23
    • 84860155499 scopus 로고    scopus 로고
    • Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice
    • Klooster R, Plomp JJ, Huijbers MG, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012;135(Pt 4):1081-1101.
    • (2012) Brain , vol.135 , pp. 1081-1101
    • Klooster, R.1    Plomp, J.J.2    Huijbers, M.G.3
  • 24
    • 84858155813 scopus 로고    scopus 로고
    • Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects
    • Viegas S, Jacobson L, Waters P, et al. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 2012;234:506-512.
    • (2012) Exp Neurol , vol.234 , pp. 506-512
    • Viegas, S.1    Jacobson, L.2    Waters, P.3
  • 25
    • 84864818526 scopus 로고    scopus 로고
    • Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors
    • Morsch M, Reddel SW, Ghazanfari N, et al. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors. Exp Neurol 2012;237:286-295.
    • (2012) Exp Neurol , vol.237 , pp. 286-295
    • Morsch, M.1    Reddel, S.W.2    Ghazanfari, N.3
  • 26
    • 84856022505 scopus 로고    scopus 로고
    • Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis
    • Mori S, Kubo S, Akiyoshi T, et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012;180:798-810.
    • (2012) Am J Pathol , vol.180 , pp. 798-810
    • Mori, S.1    Kubo, S.2    Akiyoshi, T.3
  • 27
    • 84903544751 scopus 로고    scopus 로고
    • Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction
    • Ghazanfari NM, Morsch M, Reddel SW, et al. Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction. J Physiol 2014;592:2881-2897.
    • (2014) J Physiol , vol.592 , pp. 2881-2897
    • Ghazanfari, N.M.1    Morsch, M.2    Reddel, S.W.3
  • 28
    • 77955293046 scopus 로고    scopus 로고
    • Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction
    • Maselli RA, Arredondo J, Cagney O, et al. Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction. Hum Mol Genet 2010;19:2370-2379.
    • (2010) Hum Mol Genet , vol.19 , pp. 2370-2379
    • Maselli, R.A.1    Arredondo, J.2    Cagney, O.3
  • 29
    • 84859978028 scopus 로고    scopus 로고
    • Acute severe animal model of antimuscle-specific kinase myasthenia: Combined postsynaptic and presynaptic changes
    • Richman DP, Nishi K, Morell SW, et al. Acute severe animal model of antimuscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol 2012;69:453-460.
    • (2012) Arch Neurol , vol.69 , pp. 453-460
    • Richman, D.P.1    Nishi, K.2    Morell, S.W.3
  • 30
    • 79958743273 scopus 로고    scopus 로고
    • Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice
    • Punga AR, Lin S, Oliveri F, et al. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp Neurol 2011;230:207-217.
    • (2011) Exp Neurol , vol.230 , pp. 207-217
    • Punga, A.R.1    Lin, S.2    Oliveri, F.3
  • 31
    • 84857914720 scopus 로고    scopus 로고
    • Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis
    • Mori S, Yamada S, Kubo S, et al. Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J Neuroimmunol 2012;244:1-7.
    • (2012) J Neuroimmunol , vol.244 , pp. 1-7
    • Mori, S.1    Yamada, S.2    Kubo, S.3
  • 32
    • 84890823064 scopus 로고    scopus 로고
    • MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4
    • Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA 2013;110:20783-20788. Along with Koneczny et al. establishing that disruption of normal MuSK interaction with Lrp4 may account for the functional role of MuSK antibodies. The mechanism is suggested to be antibody binding to a domain 1 epitope that inhibits the normal interaction between MuSK and Lrp4 thereby preventing agrin-induced activation of MuSK.
    • (2013) Proc Natl Acad Sci USA , vol.110 , pp. 20783-20788
    • Huijbers, M.G.1    Zhang, W.2    Klooster, R.3
  • 33
    • 84892393537 scopus 로고    scopus 로고
    • MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters
    • Koneczny I, Cossins J, Waters P, et al. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS One 2013;8:e80695. Along with Huijbers et al. establishing that disruption of normal MuSK interaction with Lrp4 on agrin signalling may account for the functional role of MuSK IgG4 subclass antibodies. However, it is also suggested that the IgG1-3 subclasses may have their own distinct effects inhibiting agrin-induced AChR clustering.
    • (2013) PLoS One , vol.8 , pp. e80695
    • Koneczny, I.1    Cossins, J.2    Waters, P.3
  • 34
    • 77956275172 scopus 로고    scopus 로고
    • Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice
    • Cole RN, Ghazanfari N, Ngo ST, et al. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010;588(Pt 17):3217-3229.
    • (2010) J Physiol , vol.588 , pp. 3217-3229
    • Cole, R.N.1    Ghazanfari, N.2    Ngo, S.T.3
  • 35
    • 13144277543 scopus 로고    scopus 로고
    • Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis
    • Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005;57:289-293.
    • (2005) Ann Neurol , vol.57 , pp. 289-293
    • Shiraishi, H.1    Motomura, M.2    Yoshimura, T.3
  • 36
    • 77953633370 scopus 로고    scopus 로고
    • A systematic review of population based epidemiological studies in myasthenia gravis
    • Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010;10:46.
    • (2010) BMC Neurol , vol.10 , pp. 46
    • Carr, A.S.1    Cardwell, C.R.2    McCarron, P.O.3    McConville, J.4
  • 37
    • 45249113530 scopus 로고    scopus 로고
    • Myasthenia gravis seronegative for acetylcholine receptor antibodies
    • Vincent A, Leite MI, Farrugia ME, et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008;1132:84-92.
    • (2008) Ann N Y Acad Sci , vol.1132 , pp. 84-92
    • Vincent, A.1    Leite, M.I.2    Farrugia, M.E.3
  • 38
    • 33745645882 scopus 로고    scopus 로고
    • Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5
    • Niks EH, Kuks JB, Roep BO, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006;66:1772-1774.
    • (2006) Neurology , vol.66 , pp. 1772-1774
    • Niks, E.H.1    Kuks, J.B.2    Roep, B.O.3
  • 41
    • 0023489792 scopus 로고
    • The treatment of Guillain-Barre syndrome by modified plasma exchange: A cost effective method for developing countries
    • De Silva HJ, Gamage R, Herath HK, et al. The treatment of Guillain-Barre syndrome by modified plasma exchange: a cost effective method for developing countries. Postgrad Med J 1987;63:1079-1081.
    • (1987) Postgrad Med J , vol.63 , pp. 1079-1081
    • De Silva, H.J.1    Gamage, R.2    Herath, H.K.3
  • 42
    • 0028779203 scopus 로고
    • Myasthenia gravis
    • Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797-1810.
    • (1994) N Engl J Med , vol.330 , pp. 1797-1810
    • Drachman, D.B.1
  • 43
    • 77956395013 scopus 로고    scopus 로고
    • Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis
    • Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010;23:530-535.
    • (2010) Curr Opin Neurol , vol.23 , pp. 530-535
    • Guptill, J.T.1    Sanders, D.B.2
  • 44
    • 82955228943 scopus 로고    scopus 로고
    • Anti-MuSK autoantibodies block binding of collagen Q to MuSK
    • Kawakami Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011;77:1819-1826.
    • (2011) Neurology , vol.77 , pp. 1819-1826
    • Kawakami, Y.1    Ito, M.2    Hirayama, M.3
  • 45
    • 84877828612 scopus 로고    scopus 로고
    • Pyridostigmine but not 3, 4-dia-minopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody
    • Morsch M, Reddel SW, Ghazanfari N, et al. Pyridostigmine but not 3, 4-dia-minopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody. J Physiol 2013;591(Pt 10):2747-2762. A demonstration in the passive transfer mouse model of a deleterious effect of chronic pyridostigmine, with both electrophysiologic and clinical deterioration resulting from this, traditionally first line, therapy for myasthenia. The findings are consistent with the known maintenance pathways for the endplate in development and suggest these also operate at the mature neuromuscular junction.
    • (2013) J Physiol , vol.591 , pp. 2747-2762
    • Morsch, M.1    Reddel, S.W.2    Ghazanfari, N.3
  • 46
    • 77952144985 scopus 로고    scopus 로고
    • Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7
    • Lashley D, Palace J, Jayawant S, et al. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 2010;74:1517-1523.
    • (2010) Neurology , vol.74 , pp. 1517-1523
    • Lashley, D.1    Palace, J.2    Jayawant, S.3
  • 47
    • 80054848752 scopus 로고    scopus 로고
    • Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia
    • Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 2011;44:789-794.
    • (2011) Muscle Nerve , vol.44 , pp. 789-794
    • Liewluck, T.1    Selcen, D.2    Engel, A.G.3
  • 48
    • 84895558244 scopus 로고    scopus 로고
    • Effects of the beta-2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis
    • Ghazanfari N, Morsch M, Tse N, et al. Effects of the beta-2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis. PLoS One 2014;9:e87840. This study shows a clinical benefit in a passive transfer MuSK-Ab mouse model from salbutamol infusion, tested on the basis that it is effective in a congenital myasthenic syndrome associated with mutations in Dok7, a MuSKcofactor protein. However, the mechanism for the apparent benefit could not be determined.
    • (2014) PLoS One , vol.9 , pp. e87840
    • Ghazanfari, N.1    Morsch, M.2    Tse, N.3
  • 49
    • 0031856826 scopus 로고    scopus 로고
    • Safety of plasmapheresis in the treatment of neurological disease
    • Vucic S, Davies L. Safety of plasmapheresis in the treatment of neurological disease. Aust N Z J Med 1998;28:301-305.
    • (1998) Aust N z J Med , vol.28 , pp. 301-305
    • Vucic, S.1    Davies, L.2
  • 50
    • 84873049650 scopus 로고    scopus 로고
    • A retrospective study of complications of therapeutic plasma exchange in myasthenia
    • Guptill JT, Oakley D, Kuchibhatla M, et al. A retrospective study of complications of therapeutic plasma exchange in myasthenia. Muscle Nerve 2013;47:170-176. This study confirms that the risks of plasmapheresis are largely due to implanted intravenous catheters and not the procedure itself. This supports use of peripheral access plasmapheresis when using this important treatment for MuSK-Ab myasthenia gravis.
    • (2013) Muscle Nerve , vol.47 , pp. 170-176
    • Guptill, J.T.1    Oakley, D.2    Kuchibhatla, M.3
  • 51
    • 0034641233 scopus 로고    scopus 로고
    • Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:7-15.
    • (2000) Neurology , vol.55 , pp. 7-15
    • Gronseth, G.S.1    Barohn, R.J.2
  • 52
    • 13244295348 scopus 로고    scopus 로고
    • Thymus changes in anti-MuSK-positive and -negative myasthenia gravis
    • Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005;64:536-538.
    • (2005) Neurology , vol.64 , pp. 536-538
    • Lauriola, L.1    Ranelletti, F.2    Maggiano, N.3
  • 53
    • 20044374002 scopus 로고    scopus 로고
    • Fewer thymic changes in MuSK antibodypositive than in MuSK antibody-negative MG
    • Leite MI, Strobel P, Jones M, et al. Fewer thymic changes in MuSK antibodypositive than in MuSK antibody-negative MG. Ann Neurol 2005;57:444-448.
    • (2005) Ann Neurol , vol.57 , pp. 444-448
    • Leite, M.I.1    Strobel, P.2    Jones, M.3
  • 54
    • 45249105334 scopus 로고    scopus 로고
    • Response to therapy in myasthenia gravis with anti-MuSK antibodies
    • Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008;1132:76-83.
    • (2008) Ann N Y Acad Sci , vol.1132 , pp. 76-83
    • Evoli, A.1    Bianchi, M.R.2    Riso, R.3
  • 55
    • 33644528477 scopus 로고    scopus 로고
    • High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies
    • Lin PT, Martin BA, Weinacker AB, So YT. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve 2006;33:433-435.
    • (2006) Muscle Nerve , vol.33 , pp. 433-435
    • Lin, P.T.1    Martin, B.A.2    Weinacker, A.B.3    So, Y.T.4
  • 56
    • 33645328823 scopus 로고    scopus 로고
    • Successful treatment of MuSK antibody positive myasthenia gravis with rituximab
    • Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody positive myasthenia gravis with rituximab. Muscle Nerve 2006;33:575-580.
    • (2006) Muscle Nerve , vol.33 , pp. 575-580
    • Hain, B.1    Jordan, K.2    Deschauer, M.3    Zierz, S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.